We are live on ! Find out more
BIIB icon

Biogen

1,004 hedge funds and large institutions have $33.4B invested in Biogen in 2023 Q4 according to their latest regulatory filings, with 135 funds opening new positions, 287 increasing their positions, 376 reducing their positions, and 81 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more first-time investments, than exits

New positions opened: 135 | Existing positions closed: 81

56% more capital inflows, than outflows

Capital inflows: $2.68B | Capital outflows: $1.72B

29% more call options, than puts

Call options by funds: $645M | Put options by funds: $499M

4% more funds holding

Funds holding: 966 → 1,004 (+38)

2.51% more ownership

Funds ownership: 86.52% → 89.04% (+2.5%)

24% less repeat investments, than reductions

Existing positions increased: 287 | Existing positions reduced: 376

27% less funds holding in top 10

Funds holding in top 10: 15 → 11 (-4)

Holders
1,004
Holders Change
+38
Holders Change %
+3.93%
% of All Funds
14.59%
Holding in Top 10
11
Holding in Top 10 Change
-4
Holding in Top 10 Change %
-26.67%
% of All Funds
0.16%
New
135
Increased
287
Reduced
376
Closed
81
Calls
$645​M
Puts
$499​M
Net Calls
+$146​M
Net Calls Change
+$89​M

BIIB Hedge Fund Activity: Q4 2023 in Review

1,004 of the 6,880 institutional investors tracked by Wall St. Rank reported a position in Biogen (BIIB) for Q4 2023, worth a combined $33.4B — up 3.5% from $32.2B a quarter earlier.

Buyers outnumbered sellers: 135 funds opened new BIIB positions and 81 closed out — a net gain of 54 holders — while 287 added to existing stakes and 376 trimmed.

The largest buyer was Vanguard Group, adding an estimated $545M. The largest seller was Samlyn Capital, exiting entirely with an estimated $108M sold.

  • 1,004 institutional investors held Biogen (BIIB) as of Q4 2023, up from 966 in Q3 2023.
  • Funds reported $33.4B of Biogen stock for Q4 2023, up 3.5% quarter-over-quarter.
  • 135 funds opened new Biogen positions in Q4 2023 and 81 closed out, a net change of +54 holders.
  • The largest Biogen buyer in Q4 2023 was Vanguard Group, an estimated $545M added.
  • The largest Biogen seller in Q4 2023 was Samlyn Capital, an estimated $108M sold.

Based on aggregated 13F filings for Q4 2023.